Cancers

HER2-low and HER2-ultralow metastatic breast cancer and trastuzumab deruxtecan: Common clinical questions and answers

Biomedicines

Cryotherapy as a surgical de-escalation strategy in breast cancer: Techniques, complications, and oncological outcomes

eLife

Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer

Annals of Oncology

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: Final overall survival analysis of the phase 3 TROPION-Breast01 study

Anti-Cancer Research

Radiological complete response as a prognostic marker in HR-positive metastatic breast cancer treated with CDK4/6 inhibitors: Implications for treatment de-escalation

Anti-Cancer Drugs

Efficacy and safety of fulvestrant combined with abemaciclib in patients with hormone receptor-positive advanced breast cancer

The Breast

How should we manage abemaciclib in the peri-operative period during secondary breast reconstruction: Balancing oncologic benefit and surgical safety

Breast Cancer Research and Treatment

Prognosis and endocrine therapy efficacy in early breast cancer with estrogen receptor low expression

JAMA

Risk-based vs annual breast cancer screening: The WISDOM randomized clinical trial

Cancer Treatment Reviews

Mechanisms and biomarkers for musculoskeletal signs and symptoms in patients treated with aromatase inhibitors: A comprehensive systematic review